Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia

Cell Signaling Technology, Inc., 3 Trask Lane, Danvers, MA 01923, USA.
Blood (Impact Factor: 10.43). 01/2007; 108(13):4202-4. DOI: 10.1182/blood-2006-06-026666
Source: PubMed

ABSTRACT The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, 8 fusion partners of FGFR1 have been identified. However, no primary leukemia cell lines were identified that contain any of these fusions. Here, we screened more than 40 acute myeloid leukemia cell lines for constitutive phosphorylation of STAT5 and applied an immunoaffinity profiling strategy to identify tyrosine-phosphorylated proteins in the KG-1 cell line. Mass spectrometry analysis of KG-1 cells revealed aberrant tyrosine phosphorylation of FGFR1. Subsequent analysis led to the identification of a fusion of the FGFR1OP2 gene to the FGFR1 gene. Small interfering RNA (siRNA) against FGFR1 specifically inhibited the growth and induced apoptosis of KG-1 cells. Thus, the KG-1 cell line provides an in vitro model for the study of FGFR1 fusions associated with leukemia and for the analysis of small molecule inhibitors against FGFR1 fusions.

Download full-text


Available from: Michael J Comb, Aug 23, 2015
  • Source
    • "Interestingly, immunoblotting results show that FGFR1 as a receptor tyrosine kinase is co-localized with PDHK1 and its substrate PDHA1 in mitochondria (Figure 1D right). Moreover, TKI258 treatment significantly decreased phosphorylation levels of PDHA1 at S293 in human myeloid leukemia KG1a cells harboring a FOP2-FGFR1 fusion protein (Gu et al., 2006) (Figure 1E; left) and lung cancer NCI-H1299 cells overexpressing FGFR1 (Marek et al., 2009) (Figure 1E; right). In consonance with this, targeting PDHK1 by a PDHK inhibitor, dichloroacetate (DCA), or shRNA results in decreased S293 phosphorylation levels of PDHA1 in FGFR1-expressing cancer cells (Figure 1F). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many tumor cells rely on aerobic glycolysis instead of oxidative phosphorylation for their continued proliferation and survival. Myc and HIF-1 are believed to promote such a metabolic switch by, in part, upregulating gene expression of pyruvate dehydrogenase (PDH) kinase 1 (PDHK1), which phosphorylates and inactivates mitochondrial PDH and consequently pyruvate dehydrogenase complex (PDC). Here we report that tyrosine phosphorylation enhances PDHK1 kinase activity by promoting ATP and PDC binding. Functional PDC can form in mitochondria outside of the matrix in some cancer cells and PDHK1 is commonly tyrosine phosphorylated in human cancers by diverse oncogenic tyrosine kinases localized to different mitochondrial compartments. Expression of phosphorylation-deficient, catalytic hypomorph PDHK1 mutants in cancer cells leads to decreased cell proliferation under hypoxia and increased oxidative phosphorylation with enhanced mitochondrial utilization of pyruvate and reduced tumor growth in xenograft nude mice. Together, tyrosine phosphorylation activates PDHK1 to promote the Warburg effect and tumor growth.
    Molecular cell 12/2011; 44(6):864-77. DOI:10.1016/j.molcel.2011.10.015 · 14.46 Impact Factor
  • Source
    • "10589_1&isoform_ nameϭIsoform_1, last accessed August 26, 2006) for consensus functional structure searches, and the Imperial College Protein Homology/ Analogy Recognition Engine (ϳphyre/, last accessed August 26, 2006 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Wounds created in the oral cavity heal rapidly and leave minimal scarring. We have examined a role of a previously isolated cDNA from oral wounds encoding wound inducible transcript-3.0 (wit3.0), also known as fibroblast growth factor receptor 1 oncogene partner 2 (FGFR1OP2). FGFR1OP2/wit3.0 was highly expressed in oral wound fibroblasts without noticeable up-regulation of alpha-smooth muscle actin. In silico analyses, denaturing and nondenaturing gel Western blot, and immunocytology together demonstrated that FGFR1OP2/wit3.0 were able to dimerize and oligomerize through coiled-coil structures and appeared to associate with cytoskeleton networks in oral wound fibroblasts. Overexpression of FGFR1OP2/wit3.0 increased the floating collagen gel contraction of naïve oral fibroblasts to the level of oral wound fibroblasts, which was in turn attenuated by small-interfering RNA knockdown. The FGFR1OP2/wit3.0 synthesis did not affect the expression of collagen I as well as procontractile peptides such as alpha-smooth muscle actin, and transforming growth factor-beta1 had no effect on FGFR1OP2/wit3.0 expression. Fibroblastic cells derived from embryonic stem cells carrying FGFR1OP2/wit3.0 (+/-) mutation showed significant retardation in cell migration. Thus, we postulate that FGFR1OP2/wit3.0 may regulate cell motility and stimulate wound closure. FGFR1OP2/wit3.0 was not up-regulated during skin wound healing; however, when treated with FGFR1OP2/wit3.0 -expression vector, the skin wound closure was significantly accelerated, resulting in the limited granulation tissue formation. Our data suggest that FGFR1OP2/wit3.0 may possess a therapeutic potential for wound management.
    American Journal Of Pathology 12/2009; 176(1):108-21. DOI:10.2353/ajpath.2010.090256 · 4.60 Impact Factor
  • Source
    • "Recent advances in methods to profile phosphotyrosine signaling have enabled analysis of known model systems (Rush et al., 2005; Wolf-Yadlin et al., 2006) and several hematological cancers (Gu et al., 2006; Walters et al., 2006). Here we broadly survey tyrosine kinase signaling across many lung cancer cell lines and solid tumors in order to classify them based upon aberrant tyrosine kinase signaling. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the success of tyrosine kinase-based cancer therapeutics, for most solid tumors the tyrosine kinases that drive disease remain unknown, limiting our ability to identify drug targets and predict response. Here we present the first large-scale survey of tyrosine kinase activity in lung cancer. Using a phosphoproteomic approach, we characterize tyrosine kinase signaling across 41 non-small cell lung cancer (NSCLC) cell lines and over 150 NSCLC tumors. Profiles of phosphotyrosine signaling are generated and analyzed to identify known oncogenic kinases such as EGFR and c-Met as well as novel ALK and ROS fusion proteins. Other activated tyrosine kinases such as PDGFRalpha and DDR1 not previously implicated in the genesis of NSCLC are also identified. By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.
    Cell 01/2008; 131(6):1190-203. DOI:10.1016/j.cell.2007.11.025 · 33.12 Impact Factor
Show more